Genprex, Inc. Genprex or the Company Nasdaq Gnpx , a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, toda
Why Is Genprex, Inc. (GNPX) Stock Down Today?
Updated Nov 22, 2026 7:10 AM ET ยท Prev Close $1.67
Session Regime & Catalyst Assessment
68% Signal ConvictionGenprex, Inc. Pulling Back 13.17% on 0.77x Relative Volume
Genprex, Inc. (GNPX) is pulling back 13.17% (-$0.22) to $1.45 on 0.77x average session volume. Relative to benchmarks, GNPX is lagging the S&P 500 by -9.53%. 14-day RSI stands at 26.6, keeping momentum in a oversold regime.
Genprex, Inc. Genprex or the Company Nasdaq Gnpx , a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, toda
Price ($1.45) trades relative to 20-day SMA ($2.00) and 50-day SMA ($2.48).
Market & Sector Relative Strength
GNPX lagging the S&P 500 by -9.53%Options Flow & Execution Desk
Recent GNPX Catalyst Headlines
Verified WireGenprex, Inc. Genprex or the Company Nasdaq Gnpx , a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, toda
Genprex, Inc. Genprex or the Company Nasdaq Gnpx , a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, toda
Genprex, Inc. Genprex or the Company Nasdaq Gnpx , a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, toda
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.45 (session support) for directional breakout confirmation.
Technical Regime (GNPX)
BEARISH MA TRENDRetail & Crowd Sentiment
NeutralBearish sentiment prevails on StockTwits regarding $GNPX with no new information from Yahoo Finance news.
About Genprex, Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System โฆ
Get Instant GNPX Catalyst Alerts
Receive an email alert when GNPX triggers an unusual volume breakout, options sweep, or rating shift.
GNPX Session & Catalyst FAQ
Why is GNPX stock down today?
Genprex, Inc. (GNPX) is pulling back 13.17% (-$0.22) to $1.45 on 0.77x average session volume. Relative to benchmarks, GNPX is lagging the S&P 500 by -9.53%. 14-day RSI stands at 26.6, keeping momentum in a oversold regime.
Is GNPX stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.77x relative volume (low participation). Our multi-factor model currently rates GNPX as HOLD. Review full valuation, quality, and timing signals on the GNPX Buy or Sell Decision Brief โ
What is GNPX's intrinsic value and expected trading range?
At $1.45, GNPX's modeled 1-to-3 session range is $1.37 โ $1.53, with a key inflection level at $1.45 (session support). Compare current price against multi-year cash flow projections in the GNPX Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for GNPX?
RSI at 26.6 indicates oversold conditions โ watch for mean-reversion support. GNPX trades at $1.45 relative to its 20-day SMA ($2.00) and 50-day SMA ($2.48), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.